Eloctate ITI

DRUG2 trials

Sponsors

Margaret Ragni

Conditions

Hemophilia A With InhibitorSevere Hemophilia A

Phase 3

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

WithdrawnNCT02196207

Margaret RagniSevere Hemophilia A

Start: 2020-08-31End: 2027-07-31Updated: 2019-08-20

The Hemophilia Inhibitor Eradication Trial

TerminatedNCT04303572

Margaret RagniHemophilia A With Inhibitor

Start: 2021-11-01End: 2022-06-27Updated: 2023-02-21

Related Papers

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Blood2023-02-0316 citations

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors

BMJ Open2022-03-017 citations

Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Blood2020-11-04